High Intrapatient Tacrolimus Variability Is Associated with Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime

Transplantation

Volumn 101, Issue 2, 2017, Pages 430-436

  Whalen, Henry R ^a,b   Glen, Julie A ^a   Harkins, Victoria ^c   Stevens, Katherine K ^a   Jardine, Alan G ^a,b   Geddes, Colin C ^a   Clancy, Marc J ^a,b  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS; CALCINEURIN INHIBITOR;

ACUTE GRAFT REJECTION; ALCOHOL CONSUMPTION; ALLOGRAFT; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HAZARD RATIO; HUMAN; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PATIENT COMPLIANCE; PATIENT EDUCATION; TREATMENT OUTCOME; ACUTE DISEASE; ADULT; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DRUG EFFECTS; ELECTRONIC HEALTH RECORD; GRAFT REJECTION; IMMUNOLOGY; KAPLAN MEIER METHOD; KIDNEY; KIDNEY DISEASE; MIDDLE AGED; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; SCOTLAND; TIME FACTOR;

ACUTE DISEASE; ADULT; AGED; CALCINEURIN INHIBITORS; DISEASE-FREE SURVIVAL; DRUG MONITORING; DRUG THERAPY, COMBINATION; ELECTRONIC HEALTH RECORDS; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCOTLAND; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84960193273     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001129     Document Type: Article

References (22)

1. Matas AJ Smith JM Skeans MA. Special issue: organ procurement and transplantation network and scientific registry of transplant recipients 2011 data report. OPTN/SRTR 2011 annual data report. Am J Transplant. 2013; 13: 11.
2. Recipients OPaTNaSRoT. Department of Health and Human Services, Health Resources and Services administration, Healthcare Systems Bureau, Division of Transplantation (ed). Am J Transplant. 2012; 13 (Suppl 1): 11-46.
3. Dunn TB Browne BJ Gillingham KJ. Selective re-transplant after graft loss to non-adherence: success with a second chance. Am J Transplant. 2009; 9: 1337-1346.
4. Pinsky BW Takemoto SK Lentine KL. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant. 2009; 9: 2597-2606.
5. Kahan BD Welsh M Urbauer DL. Low intra-individual variability of cyclosporine A exposure reduces chronic rejection incidence and health care cost. J Am Soc Nephrol. 2000; 11: 1122-1131.
6. Pollock-Barziv SM Finkelstein Y Manlhiot C. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr Transplant. 2010; 13: 968-975.
7. Borra LC Roodnat JI Kal JA. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcomes after kidney transplantation. Nephrol Dial Transplant. 2010; 25: 2757-2763.
8. Waiser J Slowinski T Brinker-Paschke A. Impact of the variability of cyclosporine A trough levels on long-term renal allograft function. Nephrol Dial Transplant. 2002; 17: 1310-1317.
9. Ekberg H Tedesco-Silva H Demirbas A. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357: 2562-2575.
10. Davidson J Wilkinson AH Dantal J. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation. 2003; 7: SS3-SS24.
11. Wilkinson AH Davidson J Dotta F. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant. 2005; 19: 291-298.
12. Sapir-Pichhadze R Wang Y Famure O. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014; 85: 1404-1411.
13. Annunziato RA Emre S Shneider BL. Transitioning health care responsibility from caregivers to patient: a pilot study aiming to facilitate medication adherence during this process. Pediatr Transplant. 2008; 12: 309-315.
14. Vicari-Christensen M Repper S Basile S. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Prog Transplant. 2009; 19: 277-284.
15. Morrissey PE Reinert S Yango A. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. Transplant Proc. 2005; 37: 2044-2047.
16. Wu MJ Cheng CY Chen CH. Lower variability of tacrolimus trough concentration after conversion from prograf to advograf in stable transplant recipients. Transplantation. 2011; 92: 648-652.
17. Tinti F Mecule A Poli L. Improvement in graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc. 2010; 42: 4047.
18. Sessa A Esposita A Iavicoli G. Cardiovascular risk factors in renal transplant patients after switch from standard tacrolimus to prolonged release tacrolimus. Transplant Proc. 2012; 44: 1901-1906.
19. Gaber AO Alloway RR Bodziak K. Conversion from twice-daily to once-daily extended release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. Transplantation. 2013; 96: 191-197.
20. Joosten SA van Kooten C Sijpkens YW. The pathobiology of chronic allograft nephropathy: immune-mediated damage and accelerated aging. Kidney Int. 2004; 65: 1556-1559.
21. Watson C Johnson R Birch R. A simplified donor risk index for predicting outcome after deceased donor kidney transplantation. Transplantation. 2012; 93: 314-318.
22. Su VC Greanya ED Ensom MH. Impact of mycophenolate mofetil dose reductions on allograft outcomes in kidney transplant recipients on tacrolimus based regimes. Ann Pharmacother. 2011; 45: 248-257.